Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 11—November 2014

Multidrug-Resistant IncA/C Plasmid in Vibrio cholerae from Haiti

Jason P. FolsterComments to Author , Lee Katz, Andre McCullough, Michele B. Parsons, Kristen Knipe, Scott A. Sammons, Jacques Boncy, Cheryl Lea Tarr, and Jean M. Whichard
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J.P. Folster, L. Katz, M.B. Parsons, K. Knipe, S.A. Sammons, C.L. Tarr, J.M. Whichard); International Health Resources Consulting, Atlanta (A. McCullough); Laboratoire National de Santé Publique, Port-au-Prince, Haiti (J. Boncy)

Main Article


Susceptibility, resistance genes, and plasmids associated with Haiti Vibrio cholerae outbreak isolates

Isolate Resistance profiles [MIC mg/L]* Resistance genes/mutations Plasmids
V. cholerae
STR [>64], FIS [>256], TMP/SXT [>4], CIP(I) [0.5], NAL [>32]
strAB sul2, dfrA1, floR, gyrA(S83I)/parC(S85L)
V. cholerae
AMP [>32], AMC [>32], CRO [>64], FOX [32], TIO [>8], CHL(I) [16], GEN [>8], STR [>64], FIS [>256], TMP/SXT [>4], TET(I) [8], CIP(I) [0.5], NAL [>32]
blaCMY-2, blaCTX-M-2, blaTEM-1, floR, aac(3)-IIa ,strAB, sul2, dfrA1, dfrA27, tetA, mphA, gyrA(S83I)/parC(S85L)
Escherichia coli DH10B
p2012EL-2176 AMP [>32], AMC [>32], CRO [>64], FOX [>32], TIO [>8], AZM [>16], CHL [>32], GEN [>8], STR [>64],† FIS [>256], TMP/SXT [>4], TET [32] blaCMY-2, blaCTX-M-2, blaTEM-1, mphA, floR, aac(3)-IIa. strAB, sul2, dfrA27, tetA IncA/C2

*Drugs tested were AMP, ampicillin; AMC, amoxicillin/clavulanic acid; AZM, azithromycin; CHL, chloramphenicol; CIP, ciprofloxacin; CRO, ceftriaxone; FIS, sulfisoxazole; FOX, cefoxitin; GEN, gentamicin; KAN, kanamycin; NAL, nalidixic acid; STR, streptomycin; TET, tetracycline; TIO, ceftiofur; and TMP/SXT, trimethoprim/sulfamethoxazole; S83I, serine-to-isoleucine change at amino acid position 83; S85L, serine-to-leucine change at amino acid position 85. Drugs that yielded intermediate results are followed by (I). Clinical Laboratory Standards Institute break points are not established for AZM. The AZM break points used in this study (>16 mg/L) were established by the National Antimicrobial Resistance Monitoring System and should not be used to predict clinical efficacy.
E. coli DH10B is intrinsically resistant to STR.

Main Article

Page created: October 20, 2014
Page updated: October 20, 2014
Page reviewed: October 20, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.